Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | EIF4E | P06730 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12786977 | 0.80 | FBP1 (0.36) | TLR8MEN1KMT2AATMCYP19A1 | |
| SCHEMBL12786978 | 0.71 | RET (0.55) | RETLCKSMN1; SMN2 | |
| SCHEMBL6002911 | 0.69 | TLR8 (0.43) | TLR8MEN1KMT2AMAPT | |
| SCHEMBL3193066 | 0.68 | CYP19A1 (0.53) | SMN1; SMN2KMT2ACYP19A1MAPT | |
| SCHEMBL15010413 | 0.66 | SCN9A (0.36) | TLR8KMT2ASCN9A | |
| SCHEMBL5522989 | 0.64 | TLR8 (0.39) | TLR8SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL30993822 | 0.64 | TLR8 (0.39) | TLR8MEN1KMT2AMAPT | |
| SCHEMBL12786975 | 0.64 | TLR8 (0.39) | TLR8MEN1KMT2AMAPT | |
| SCHEMBL15960732 | 0.64 | TLR8 (0.52) | RETTLR8CCR6SMN1; SMN2MEN1 | |
| SCHEMBL12663393 | 0.64 | MAPT (0.36) | TLR8SMN1; SMN2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | RET, ABL1, PRKACA | RET 1/4885LCK 89/4885MAPK14 457/4885 |
| US-20080234267-A1 | Compounds and Methods of Treatment | RET, ABL1, PRKACA | RET 1/4885LCK 89/4885MAPK14 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.